CN111802633A

CN111802633A - Special clinical nutrition formula for esophageal cancer and preparation method thereof

Info

Publication number: CN111802633A
Application number: CN202010537627.6A
Authority: CN
Inventors: 尤俊; 季敬东
Original assignee: Shanghai Own Medic High Tech Medical Industrial Co ltd
Current assignee: Shanghai Own Medic High Tech Medical Industrial Co ltd
Priority date: 2020-06-12
Filing date: 2020-06-12
Publication date: 2020-10-23

Abstract

The invention discloses a special clinical nutrition formula for esophageal cancer, which comprises the following components in parts by weight: 15-45 parts of carbohydrate, 8-30 parts of protein, 0.2-1 part of folic acid, 120.0005-0.004 part of vitamin B, 0.6-2 parts of vitamin C, 0.002-0.04 part of vitamin E, 0.000001-0.00002 part of vitamin D, 0.01-0.02 part of zinc, 0.2-2 parts of calcium, 0.00005-0.00025 part of selenium, 5-20 parts of fat, 2-10 parts of new resource food, 4-30 parts of medicinal and edible components, 10-25 parts of dietary fiber and 0.00003-0.000035 parts of nucleotide. The formula provided by the invention can relieve clinical symptoms of patients, improve nutritional status of patients, relieve adverse reactions during operations, radiotherapy and chemotherapy and improve prognosis of patients through reasonable diet blending.

Description

Special clinical nutrition formula for esophageal cancer and preparation method thereof

Technical Field

The invention relates to the field of formula foods with special medical application, in particular to a special clinical nutrition formula for esophageal cancer and a preparation method thereof.

Background

Esophageal cancer is a common malignancy, with the incidence ranking at 8 th and the mortality ranking at 6 th in all malignancies. China is a high-incidence area of esophageal cancer, and the incidence rate and the fatality rate of the esophageal cancer are in the front in China. There are two main types of pathology for esophageal cancer: the most common type of malignancy of the upper esophageal segment 2/3 is squamous cell carcinoma; the most common type of pathology for the malignancy of lower segment 1/3 is adenocarcinoma. The majority of esophageal cancers in China are the first squamous cell carcinoma.

Esophageal malignancies are of the following rare types: spindle cell carcinoma (poorly differentiated squamous cell carcinoma), wart carcinoma (highly differentiated squamous cell carcinoma), pseudosarcoma, mucinous epithelial cell carcinoma, adenosquamous carcinoma, cylindroma (adenoid cystic tumor), primary oat cell carcinoma, choriocarcinoma, carcinoid carcinoma, sarcoma, and primary malignant melanoma.

Metastatic esophageal cancer accounts for 3% of esophageal cancers. Melanoma and breast cancer are the most common tumors that are prone to metastasis to the esophagus; malignant tumors of the head, neck, lung, stomach, liver, kidney, prostate, testis, and bone may also metastasize to the esophagus. Metastatic esophageal malignancies usually develop in the basal portion of the loose connective tissue around the esophagus, while primary esophageal cancer originates in the mucosa or submucosa.

Early esophageal cancer often has no obvious symptoms. When the diameter of the esophageal lumen is <14mm, patients often have manifestations of dysphagia. Patients first manifest themselves as dysphagia with solid food, then with semi-solid food, and finally with liquid food and even saliva; the continuing progression of the disease suggests that esophageal cancer is a progressive malignant course rather than spastic, benign or digestive stenosis. The patient may have chest pain and often radiates to the back.

Even with normal appetite, most patients lose weight. Compression of the recurrent laryngeal nerve can lead to paralysis of the vocal cords and hoarseness. Sympathetic nerve compression can cause Horner syndrome, and nerve compression in other areas can cause spinal pain, hiccup, and diaphragm paralysis. Malignant pleural effusion and esophageal cancer metastasis to the lung can lead to dyspnea. Tumor growth into the cavity can lead to swallowing pain, vomiting, hematemesis, dark stools, iron deficiency anemia, aspiration, and coughing. Esophago-tracheobronchial fistulas can lead to lung abscesses and pneumonia. Also includes other symptoms such as superior vena cava syndrome, malignant ascites, bone pain, etc.

Esophageal cancer often spreads to the jugular vein lymph nodes, cervical lymph nodes, supraclavicular lymph nodes, and mediastinal lymph nodes via lymphatic vessels. Esophageal cancer often metastasizes to the lung and liver, and even to distant sites such as bone, heart, brain, adrenal glands, kidneys, peritoneum.

The survival rate of patients with tumors confined to the mucosa can reach 80%, the survival rate of patients with tumors confined to the submucosa is less than 50%, the survival rate of patients with tumors confined to the submucosa is 20%, the survival rate of patients with tumors confined to the intrinsic muscularis is less than 20%, the survival rate of patients with tumors confined to the adjacent organs is 7%, and the survival rate of patients with tumors confined to the distant metastasis is. Overall, the recovery is poor, the 5-year survival rate is less than 5%, and the survival time of patients with esophageal cancer is short. The stage of the esophagus cancer after healing depends on the stage of the esophagus cancer to a great extent, but the patients lose the chance of operation in the late stage of treatment and can only be treated by palliative treatment such as radiotherapy, chemotherapy and the like. In particular, esophageal squamous carcinoma is not sensitive to chemotherapeutic drugs, and radiotherapy is limited by radiotolerance of important organs around the esophagus, such as spinal cord, lung and the like, so that sufficient target dose cannot be given, and the radiotherapy effect is greatly reduced. Therefore, the death rate of patients with esophageal cancer at present is high.

Different treatment methods are adopted for esophageal cancer of different stages, mainly surgical treatment and secondarily chemotherapy and radiotherapy. The surgical treatment of esophageal cancer is wide in range, and complications caused by the surgery can cause serious physical burden to some patients, especially to the elderly patients. The radiotherapy can effectively control the metastatic tumor focus of metastatic bone cancer and effectively relieve pain; chemotherapy can be used for symptomatic treatment and can inhibit the proliferation of tumor cells, but radiotherapy and chemotherapy have great harm to patients with metastatic bone cancer, and the patients have poor physical health conditions. Therefore, there is a need to adopt comprehensive nutritional support to improve the quality of life of patients.

Disclosure of Invention

The invention provides a special clinical nutrition formula for esophageal cancer, which solves the problems in the prior art, provides high-quality protein, n-3 and n-6 unsaturated fatty acids through reasonable diet blending, selects various vitamins, minerals, medicinal and edible foods and new resource foods, relieves the clinical symptoms of patients and improves the nutritional status of the patients.

In order to achieve the purpose, the invention adopts the following technical scheme:

the invention provides a special clinical nutrition formula for esophageal cancer, which comprises the following components in parts by weight: 15-45 parts of carbohydrate, 8-30 parts of protein, 0.2-1 part of folic acid and vitamin B₁₂0.0005-0.004 portion, 0.6-2 portions of vitamin C and vitamin0.002-0.04 part of vitamin E, 0.000001-0.00002 part of vitamin D, 0.01-0.02 part of zinc, 0.2-2 parts of calcium, 0.00005-0.00025 part of selenium, 5-20 parts of fat, 2-10 parts of new resource food, 4-30 parts of medicinal and edible components, 10-25 parts of dietary fiber and 0.00003-0.000035 parts of nucleotide.

Preferably, the new resource food comprises one or more of arginine, glutamine, probiotics and L-carnitine.

Preferably, the protein source is one or more of hydrolyzed whey protein powder, concentrated whey protein powder, soy protein isolate, whole egg powder, bovine colostrum powder, whole milk powder, albumin peptide, soybean peptide, marine fish oligopeptide, wheat oligopeptide, corn oligopeptide powder, alpha-whey protein powder and lactoferrin.

Preferably, the nucleotide comprises one or more of cytidine 5 ' -monophosphate (5-CMP), uridine 5 ' -monophosphate (5 ' -UMP), adenosine 5 ' -monophosphate (5 ' -AMP), disodium 5 ' -inosinate, disodium 5 ' -guanylate, disodium 5 ' -uridylate, disodium 5 ' -cytidylate.

Preferably, the dietary fiber is derived from one or more of cereal dietary fibers such as inulin, polydextrose, galacto-oligosaccharide, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, resistant dextrin and soybean fiber.

Preferably, the vitamin E comprises one or more of d-alpha-tocopherol, dl-alpha-tocopherol, d-alpha-tocopherol acetate, dl-alpha-tocopherol acetate, mixed tocopherol concentrate, vitamin E calcium succinate, d-alpha-tocopherol succinate, and dl-alpha-tocopherol succinate.

Preferably, the zinc is derived from one or more of zinc sulfate, zinc gluconate, zinc oxide, zinc lactate, zinc citrate, zinc chloride, zinc acetate and zinc carbonate.

Preferably, the selenium comprises one or more of sodium selenite, sodium selenate, selenoprotein, selenium-rich edible fungus powder, L-selenium-methyl selenocysteine and selenium-rich yeast.

Preferably, the probiotics comprise one or more of lactobacillus acidophilus NCFM, bifidobacterium animalis Bb-12, bifidobacterium lactis HN019, bifidobacterium lactis Bi-07, lactobacillus rhamnosus LGG, lactobacillus rhamnosus HN001, lactobacillus fermentum CECT5716 and bifidobacterium breve M-16V.

Preferably, the medicinal and edible components comprise one or more of Poria, Glycyrrhrizae radix, herba Houttuyniae, rhizoma Zingiberis recens, fructus Gardeniae, fructus Amomi, pericarpium Citri Tangerinae, herba Taraxaci, endothelium corneum Gigeriae Galli and Concha Ostreae.

In a second aspect, the invention provides a preparation method of the special clinical nutritional formula for esophageal cancer, which is characterized by comprising the following steps:

s1: weighing the raw materials according to the parts by weight in the claim 1, and mixing the vitamins, minerals, medicinal and edible food raw materials and new resource food raw materials to obtain a first mixture;

s2: mixing the first mixture obtained in the step S1 with carbohydrate and stirring to obtain a second mixture;

s3: and (5) putting the second mixture obtained in the step (S2) and other materials into a mixing stirrer according to a gradually increasing principle, and stirring to obtain the special clinical nutrition formula for the esophageal cancer.

S4: inspecting the esophageal cancer special clinical nutritional formula in the step S3; and weighing, recording and repacking after the test is qualified.

By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:

through reasonable diet blending, high-quality protein, n-3 and n-6 unsaturated fatty acid are provided, and various vitamins, mineral substances, medicinal and edible foods and new resource foods are selected, so that the clinical symptoms of patients are relieved, the nutritional status of the patients is improved, the adverse reactions during operations, chemoradiotherapy are relieved, and the prognosis of the patients is improved. The subsequent reasonable nutrition and the support of the medicine and food homologous substances simultaneously regulate the abnormal metabolism of the tumor, inhibit the growth of the tumor and finally prolong the survival time of the patient.

Detailed Description

The invention provides a special clinical nutrition formula for esophageal cancer, which comprises the following components in parts by weight: 15-45 parts of carbohydrate, 8-30 parts of protein, 0.2-1 part of folic acid and vitamin B₁₂0.0005-0.004 parts of vitamin C and 0.6-2 parts of vitamin C0.002-0.04 part of vitamin E, 0.000001-0.00002 part of vitamin D, 0.01-0.02 part of zinc, 0.2-2 parts of calcium, 0.00005-0.00025 part of selenium, 5-20 parts of fat, 2-10 parts of new resource food, 4-30 parts of medicinal and edible components, 10-25 parts of dietary fiber and 0.00003-0.000035 parts of nucleotide.

Due to the location and the range of involvement, the esophageal cancer resection has large operative trauma, and patients are in a state of high decomposition and metabolic disorder, which are generally accompanied by hypoproteinemia, and if the patients are accompanied by diabetes, the blood sugar level is unstable, the collagen synthesis in vivo is obstructed, the cellular immune function is reduced, the incidence rate of complications such as esophageal anastomotic fistula, incision nonunion, infection and the like is greatly increased.

Therefore, the nutrition support in the perioperative period must be strengthened, the nutrition condition of the patient is improved, thereby reducing the occurrence of operative complications, lightening the adverse reaction during the operation and the chemoradiotherapy, improving the prognosis of the patient, prolonging the life cycle of the patient, improving the life quality of the patient, regulating the abnormal metabolism of the tumor, inhibiting the growth of the tumor and finally prolonging the life cycle of the patient.

Nucleotides are the major components of cells and are extremely important for the normal maturation of lymphocytes. When nucleotide is deficient, the symptoms of interleukin 2, natural killer cells and macrophage decline can appear, and the body has obvious immunosuppression. Endogenous nucleotide can not meet the needs of the body, and exogenous nucleotide can be supplemented to enhance the immune function of the body, so that the loss of the immune function caused by the lack of protein in a high-decomposition state can be avoided or alleviated.

In a preferred embodiment of the present invention, the nucleotide comprises one or more of cytidine 5 '-monophosphate (5' -CMP), uridine 5 '-monophosphate (5' -UMP), adenosine 5 '-monophosphate (5' -AMP), disodium 5 '-inosinate, disodium 5' -guanylate, disodium 5 '-uridylate, disodium 5' -cytidylate.

The n-3 polyunsaturated fatty acid is a main component of cell membrane phospholipid, can reduce the formation of prostaglandin and leukotriene, reduce the generation of inflammatory factors, reduce hypersensitivity, and enhance intestinal barrier function, thereby enhancing immune function, and helps patients to obtain good prognosis by reducing postoperative infection risk.

In one embodiment of the present invention, the fat comprises one or more of fish oil microcapsule powder, linseed oil microcapsule powder, evening primrose oil microcapsule powder, olive oil microcapsule powder, chained triglyceride powder, docosahexaenoic acid oil, arachidonic acid oil, and tea oil microcapsule powder.

Glutamine is the most abundant amino acid in blood, and accounts for 50% of free amino acid in the body. 75% of the glutamine pool is present in skeletal muscle, the remainder being mainly present in the liver. In the case of a stress such as a decrease in glutamine in blood and tissues of a patient suffering from a wound or a tumor in a catabolic state or a trauma, the stored glutamine may be consumed by 50% or more, the plasma concentration may be decreased by 20% to 30%, and the release from skeletal muscle may be increased as a result of the decrease in intracellular glutamine, and the glutamine in the host tissue may be decreased.

Arginine, an essential amino acid, can improve T cell and macrophage functions and produce NO with immune defense effects. Arginine not only stimulates the release of thymus to T lymphocytes through the conduction of the nervous system, but also increases the secretory activity of mononuclear lymphocytes in spleen to interleukin 2, thereby improving the immune defense and immunoregulation action of the T lymphocytes.

In one embodiment of the invention, the probiotics comprise one or more of lactobacillus acidophilus NCFM, bifidobacterium animalis Bb-12, bifidobacterium lactis HN019, bifidobacterium lactis Bi-07, lactobacillus rhamnosus LGG, lactobacillus rhamnosus HN001, lactobacillus fermentum CECT5716 and bifidobacterium breve M-16V.

In one embodiment of the invention, the new resource food comprises one or more of arginine, glutamine, probiotics, and l-carnitine.

Further preferably, the arginine comprises one or more of L-arginine, L-arginine hydrochloride and L-arginine-aspartic acid.

In one embodiment of the invention, the protein source is one or more of hydrolyzed whey protein powder, concentrated whey protein powder, soy protein isolate, whole egg powder, bovine colostrum powder, whole milk powder, albumin peptide, soybean peptide, marine fish oligopeptide, wheat oligopeptide, corn oligopeptide powder, alpha-whey protein powder and lactoferrin.

In one embodiment of the invention, the dietary fiber is derived from one or more of cereal dietary fibers such as inulin, polydextrose, galacto-oligosaccharide, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, resistant dextrin, soybean fiber and the like.

Vitamin E can inhibit cancer by scavenging free radicals, protecting normal cells, inhibiting proliferation of cancer cells, inducing transformation of cancer cells to normal cells, and improving immunity. Vitamin E can inhibit the synthesis of nitroso compounds in vivo, thereby preventing tumor.

In a preferred embodiment of the present invention, the vitamin B₁₂Is composed of one or more of cyanocobalamine, cyanocobalamine hydrochloride and hydroxycobalamin; the vitamin C is derived from one or two of L-ascorbic acid and L-sodium ascorbate; the vitamin D is derived from one or two of cholecalciferol and ergocalciferol; the vitamin E is selected from one or more of d-alpha-tocopherol, dl-alpha-tocopherol, d-alpha-tocopherol acetate, dl-alpha-tocopherol acetate, mixed tocopherol concentrate, vitamin E calcium succinate, d-alpha-tocopherol succinate and dl-alpha-tocopherol succinate.

In a preferred embodiment of the present invention, the zinc is derived from one or more of zinc sulfate, zinc gluconate, zinc oxide, zinc lactate, zinc citrate, zinc chloride, zinc acetate, and zinc carbonate.

Selenium is a good antioxidant, can start the antitoxic action of glutathione peroxidase, can effectively remove free radicals, and protects cell membranes from being damaged by the free radicals, thereby keeping the integrity of cell nucleuses and gene components. In addition, selenium can be coordinated with vitamin E to improve antioxidant effect. An increased intake of selenium is positively correlated with a decreased incidence of tumor.

In a preferred embodiment of the present invention, the selenium comprises one or more of sodium selenite, sodium selenate, selenoprotein, selenium-enriched edible mushroom powder, L-selenium-methylselenocysteine, and selenium-enriched yeast.

Traditional Chinese medicine considers that esophageal cancer is caused by various factors such as melancholia, anger, diet, alcohol injury, old and weak, other diseases and transformation. At the beginning, pathogenic qi such as qi stagnation, phlegm obstruction, blood stasis, etc. blocks the esophagus to make it narrow; if the pathogenic factors are not removed for a long time, the body fluid and blood are consumed, the viscera are not nourished, and the esophagus is dry and astringent, so that the food and drink are difficult to be taken down. The pathogenesis includes qi depression, phlegm obstruction, blood stasis, deficiency of qi, blood and body fluid, and the like, wherein the mutual obstruction of phlegm and blood and the stagnation of toxic pathogen are the most common, and are also the main mechanisms leading to the continuous development of esophageal cancer.

The main chemical components of Poria comprise pachyman, beta-pachyman, glucose, sucrose and fructose, ergosterol, stedane, cellulose, and triterpene, octanoic acid, lauric acid, histidine, choline, protein, fat, enzyme, adenine and gum. The Chinese medicinal material is dried sclerotium of Poria cocos (Schw.) wolf of Polyporaceae. The medicinal material has mild nature and sweet taste. The pharmacological action is as follows: promoting urination; immunomodulation, including cellular and humoral immunity; anti-tumor; protecting liver.

The main chemical component of licorice is triterpene saponin, one of which is glycyrrhizin, potassium salt and calcium salt of glycyrrhizic acid produced by combining beta-glycyrrhetinic acid and glucuronic acid. Also contains flavonoids and coumarin compounds. The medicinal material has mild property and sweet taste. The pharmacological action is as follows: detoxification; anti-inflammatory and anti-allergic responses; the effects on gastric secretion; and (4) resisting cancer.

The herba Houttuyniae contains saccharide, protein, fat, calcium, phosphorus and volatile oil, and the volatile oil contains methyl n-nonyl ketone, myrcene, decanoic acid, decanol, and lauraldehyde. The medicine has pungent taste and cold nature. The pharmacological action is as follows: antibacterial; resisting viruses; enhancing immunity, and promoting phagocytic function of leukocyte and macrophage; anti-inflammatory and analgesic effects; and (3) resisting tumors.

Ginger, rhizoma Zingiberis recens, is pungent in flavor and warm in nature. The pharmacological action is as follows: affecting the digestive system, and playing a dual-phase role in the secretion of gastric acid and gastric juice. Gardenia contains geniposide, chlorogenic acid and other ingredients. The medicinal material is bitter in taste and cold in nature. The pharmacological action is as follows: tranquilizing and relieving pain; cooling and relieving heat; anti-inflammatory. Sha ren, a pungent flavor with warm nature. The pharmacological action is as follows: affecting the digestive system and promoting the peristalsis of gastrointestinal smooth muscles; increasing motilin, enhancing gastric emptying and intestinal transit, and increasing the level of motilin in plasma, antrum and jejunum tissues.

The volatile oil in pericarpium Citri Tangerinae is mainly limonene, and the medicinal material has sweet taste and cold property. The pharmacological action is as follows: the effect on digestive systems; anti-inflammatory and anti-allergic; and (4) effects on cardiovascular system. Coix seed, sweet and light in flavor, cool in nature. The pharmacological action is as follows: resisting cancer; for cardiovascular effects; and (4) resisting bacteria. The dandelion is bitter and sweet in taste and cold in nature. The pharmacological action is as follows: performing spectrum bacteriostasis; resisting stomach injury; anti-tumor; clear heat and remove toxicity, relax bowels.

Ji Nei jin is sweet in flavor and cold in nature. The pharmacological action is as follows: promoting digestion; strengthening body constitution, and delaying aging. The oyster contains calcium carbonate, calcium phosphate and calcium sulfate, and contains glycogen, taurine, 10 essential amino acids, glutathione, vitamins and the like. The medicinal material is salty in taste and slightly cold in nature. The pharmacological action is as follows: enhancing immunity; tranquilizing and relieving pain; and adjusting the electrolyte balance.

The treatment of traditional Chinese medicine mainly adopts syndrome differentiation, the symptoms are treated in case of emergency, the root cause is treated in case of slow, and both internal and external treatments are used. (1) Improving vital qi of organism, and enhancing disease resistance, disease prevention and self-repairing ability of organism; (2) improving symptoms of patients such as debilitation, spontaneous perspiration, night sweat, pain, etc.; (3) can regulate the immune function of an organism, inhibit the proliferation of tumor cells, induce the apoptosis of the tumor cells and prevent or delay the metastasis of tumors; (4) alleviate the toxic and side effects of traditional Chinese medicines with excessive power of radiotherapy and chemotherapy or attack of pathogenic factors or consume too much healthy qi, and prolong the life cycle.

The present invention will be described in detail and specifically with reference to the following examples to facilitate better understanding of the present invention, but the following examples do not limit the scope of the present invention.

Example 1

This example provides a specific clinical nutritional formula for esophageal cancer, comprising the following components (as described in table 1):

TABLE 1 clinical nutritional formula specific for esophageal cancer in example 1

The preparation method of the special clinical nutrition formula for the esophageal cancer comprises the following steps:

s1: weighing raw materials according to table 1, and mixing the vitamins, minerals, medicinal and edible source and new resource food raw materials to obtain a first mixture;

s2: mixing the first mixture obtained in the step S1 with carbohydrate, and stirring for 10min to obtain a second mixture;

s3: and (5) putting the second mixture obtained in the step (S2) and other materials into a mixing stirrer according to a gradually increasing principle, and stirring for 20min to obtain the special clinical nutrition formula for the esophageal cancer.

Example 2

This example provides a specific clinical nutritional formula for esophageal cancer, comprising the following components (as described in table 2):

TABLE 2 Special clinical nutritional formula for esophageal cancer

s1: weighing the raw materials according to table 2, and mixing the vitamins, minerals, medicinal and edible source and new source food raw materials to obtain a first mixture;

Example 3

This example provides a specific clinical nutritional formula for esophageal cancer, comprising the following components (as described in table 3):

TABLE 3 Special clinical nutritional formula for esophageal cancer

s1: weighing the raw materials according to table 3, mixing the vitamins, minerals, medicinal and edible source and new source food raw materials to obtain a first mixture;

Application example 1

The test subjects were 30 patients with esophageal cancer of similar physical conditions, and the patients were randomly divided into three groups of 10 persons each, the control group was administered with placebo, and the experimental group was administered with the esophageal cancer-specific clinical nutritional formulas provided in examples 1 to 3 at a time of 100mg for 2 months, and the weight was weighed, and the results were as shown in table 4 below.

TABLE 4 examples 1-3 Effect of the specific clinical nutritional formulas for esophageal cancer

Application example 2

1. Establishment of human esophageal carcinoma mouse tumor implantation model

1.1 taking out the necrotic tissue from the fresh tumor tissue, cutting into about 3 cubic millimeters in diameter, and inserting into the subcutaneous dorsal part of a female mouse which is 6 weeks old and about 18 g.

1.2 mice were placed into a mouse IVC system for feeding.

1.3 waiting for the tumor to form about 15mm, excising subcutaneous tumor aseptically, selecting solid mass, cutting the material into 3 cubic mm small blocks, and transplanting to another mouse.

1.4 tumor passage is carried out by the method, and mice of the third generation all appear subcutaneous transplantation tumors and have small difference of tumor sizes.

2. Treatment study of laboratory animals

Mice were evenly distributed to each group according to tumor volume, with more than 10 per group. The 2 groups of mice had free access to water at the following doses. After one month, the experiment was terminated, and the subcutaneous tumor on the back was removed and weighed, and the average value was taken.

Control group: drinking sterile distilled water;

experimental groups: the formula prepared in example 1 was infused with warm water and infused into the stomach every day.

TABLE 5 treatment study results of the Experimental animals

The embodiments of the present invention have been described in detail, but the embodiments are merely examples, and the present invention is not limited to the embodiments described above. Any equivalent modifications and substitutions to those skilled in the art are also within the scope of the present invention. Accordingly, equivalent changes and modifications made without departing from the spirit and scope of the present invention should be covered by the present invention.

Claims

1. The special clinical nutrition formula for the esophageal cancer is characterized by comprising the following components in parts by weight: 15-45 parts of carbohydrate, 8-30 parts of protein, 0.2-1 part of folic acid and vitamin B₁₂0.0005 to 0.004 portion, 0.6 to 2 portions of vitamin C, 0.002 to 0.04 portion of vitamin E, 0.000001 to 0.00002 portion of vitamin D, 0.01 to 0.02 portion of zinc, 0.2 to 2 portions of calcium, 0.00005 to 0.00025 portion of selenium, 5 to 20 portions of fat, 2 to 10 portions of new resource food, 4 to 30 portions of medicinal and edible components, 10 to 25 portions of dietary fiber and 0.00003 to 0.000035 portions of nucleotide.

2. The esophageal cancer-specific clinical nutritional formulation according to claim 1, wherein the new resource food comprises one or more of arginine, glutamine, probiotics, and l-carnitine.

3. The esophageal cancer-specific clinical nutritional formula according to claim 1, wherein the protein source is one or more of hydrolyzed whey protein powder, concentrated whey protein powder, soy protein isolate, whole egg powder, bovine colostrum powder, whole milk powder, albumin peptide, soy peptide, marine fish oligopeptide, wheat oligopeptide, corn oligopeptide powder, alpha-lactalbumin powder, and lactoferrin.

4. The esophageal cancer-specific clinical nutritional formulation according to claim 1, wherein the nucleotides comprise one or more of cytidine 5 ' -monophosphate (5-CMP), uridine 5 ' -monophosphate (5 ' -UMP), adenosine 5 ' -monophosphate (5 ' -AMP), disodium 5 ' -inosinate, disodium 5 ' -guanylate, disodium 5 ' -uridylate, and disodium 5 ' -cytidylate.

5. The clinical nutritional formula special for esophageal cancer according to claim 1, wherein the dietary fiber is derived from one or more of cereal dietary fibers such as inulin, polydextrose, galacto-oligosaccharide, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, resistant dextrin and soybean fiber.

6. The esophageal cancer-specific clinical nutritional formulation of claim 1, wherein said vitamin E comprises one or more of d-alpha-tocopherol, dl-alpha-tocopherol, d-alpha-tocopherol acetate, dl-alpha-tocopherol acetate, mixed tocopherol concentrate, calcium vitamin E succinate, d-alpha-tocopherol succinate, and dl-alpha-tocopherol succinate.

7. The esophageal cancer-specific clinical nutritional formulation according to claim 1, wherein the probiotic comprises one or more of lactobacillus acidophilus NCFM, bifidobacterium animalis Bb-12, bifidobacterium lactis HN019, bifidobacterium lactis Bi-07, lactobacillus rhamnosus LGG, lactobacillus rhamnosus HN001, lactobacillus fermentum CECT5716, and bifidobacterium breve M-16V.

8. The esophageal cancer-specific clinical nutritional formula according to claim 1, wherein the selenium comprises one or more of sodium selenite, sodium selenate, selenoprotein, selenium-rich edible fungus powder, L-selenium-methyl selenocysteine, and selenium-rich yeast.

9. The special clinical nutritional formula for esophageal cancer according to claim 1, wherein the medicinal and edible components comprise one or more of poria cocos, liquorice, houttuynia cordata, ginger, gardenia, fructus amomi, dried orange peel, dandelion, endothelium corneum gigeriae galli and oyster.

10. A method for preparing a clinical nutritional formula according to any one of claims 1 to 9, wherein the method comprises the following steps:

s2: mixing the first mixture obtained in the step S1 with carbohydrate, and stirring for 8-15min to obtain a second mixture;

s3: and (5) putting the second mixture obtained in the step (S2) and other materials into a mixing stirrer according to a gradually increasing principle, and stirring for 18-22min to obtain the special clinical nutrition formula for the esophageal cancer.